Caribou Biosciences Inc

NASDAQ:CRBU  
8.97
-0.28 (-3.03%)
7:44:48 PM EDT: $9.26 +0.29 (+3.23%)
Products

Caribou Biosciences Announces FDA Clearance Of Ind Application For Cb-011, An Allogeneic Anti-Bcma Car-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma

Published: 11/21/2022 14:47 GMT
Caribou Biosciences Inc (CRBU) - Caribou Biosciences Announces FDA Clearance of Ind Application for Cb-011, an Allogeneic Anti-bcma Car-t Cell Therapy for the Treatment of Relapsed Or Refractory Multiple Myeloma.
Caribou Biosciences Inc - Cammouflage Phase 1 Clinical Trial to Initiate Patient Enrollment at Dose Level 1 in Early 2023.